Clinical Trials
37 trialsPIPACOVA
Hospices Civils de Lyon
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
Oncoinvent Solutions AS
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Institutes of Health Clinical Center (CC)
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
University of Iowa
INSIGHT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
University of Colorado, Denver
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc.
PIPAC-NAL-IRI
University Hospital, Ghent
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
M.D. Anderson Cancer Center
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Boehringer Ingelheim
TEMPO
Duke University
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Kazia Therapeutics Limited
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
Johns Hopkins University
PIPAC
National University Hospital, Singapore
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis
National University Hospital, Singapore
Nab-PIPAC
University Hospital, Geneva
PIPAC-nabpac
University Hospital, Ghent
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis
Sichuan Clover Biopharmaceuticals, Inc.
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
University of Massachusetts, Worcester
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Celgene
Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis
The University of Hong Kong
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
City of Hope Medical Center
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Orano Med LLC
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
CritiTech, Inc.
Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
M.D. Anderson Cancer Center
Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
SU5416 and Carboplatin to Treat Ovarian Cancer
National Institutes of Health Clinical Center (CC)